Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
There were no material changes to the company's financial position reported. The only change noted is an increase in the notional allocation of Ordinary share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on July 30, 2009.
- Valuation Price: The ADRs were valued at $38.43 per share.
- Participants: The transaction involved Dr. M M Slaoui, Mrs. C Bruck Slaoui, Mr. E J Gray, Mr. W C Louv, and Dr. D Pulman.
- Allocation Details: Notional increases were 4, 1, 15, 9, and 17 ADRs respectively for the listed individuals.